Atara Biotherapeutics to Host CAR T Breakfast Teach-In on November 29, 2018
November 27 2018 - 8:30AM
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading
off-the-shelf, allogeneic T-cell immunotherapy company developing
novel treatments for patients with cancer, autoimmune and viral
diseases, today announced that the Company will host a live
conference call and webcast in conjunction with its CAR T Breakfast
Teach-In on Thursday, November 29, 2018 at 7:30 a.m. EST in New
York, NY.
The event features next generation CAR T experts:
- Michel Sadelain, M.D., Ph.D., Director, Center for Cell
Engineering, Memorial Sloan Kettering Cancer Center (MSK)
- Marco Davila, M.D., Ph.D., Associate Attending Physician,
Department of Blood & Marrow Transplantation and Cellular
Immunotherapy Medical Director, Cell Therapy Facility, Moffitt
Cancer Center
Analysts and investors can participate in the event via
conference call by dialing (888) 540-6216 for domestic callers and
(734) 385-2715 for international callers, using the conference ID
8898797. The live webcast can be accessed on the Investors and
Media section of Atarabio.com. A replay of the webcast will be
available on the Company’s website for 30 days following the live
conference call.
About Atara Biotherapeutics, Inc.Atara
Biotherapeutics, Inc. (@Atarabio) is a leading off-the-shelf,
allogeneic T-cell immunotherapy company developing novel treatments
for patients with cancer, autoimmune and viral diseases. Atara’s
most advanced T-cell immunotherapy, tab-cel® (tabelecleucel), is in
Phase 3 development for patients with Epstein-Barr virus associated
post-transplant lymphoproliferative disorder (EBV+ PTLD), as well
as other EBV associated hematologic and solid tumors, including
nasopharyngeal carcinoma (NPC). Atara is also developing T-cell
immunotherapies targeting EBV antigens believed to be important for
the potential treatment of multiple sclerosis (MS). Atara's
pipeline also includes next generation chimeric antigen receptor
T-cell (CAR T) immunotherapies for patients with hematologic and
solid tumors, autoimmune and infectious diseases. The company was
founded in 2012 and is headquartered in South San Francisco,
California.
INVESTOR & MEDIA CONTACTS:
Investors:John Craighead, Atara
Biotherapeutics650-410-3012jcraighead@atarabio.com
John Grimaldi, Burns McClellan212-213-0006
x362jgrimaldi@burnsmc.com
Media:Nancie Steinberg, Burns
McClellan212-213-0006 x318nsteinberg@burnsmc.com
Atara Biotherapeutics (NASDAQ:ATRA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Atara Biotherapeutics (NASDAQ:ATRA)
Historical Stock Chart
From Apr 2023 to Apr 2024